Technical Analysis for PRLD - Prelude Therapeutics Incorporated
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 4.04 | 4.39% | 0.17 |
Earnings due: May 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 4.39% | |
| Oversold Stochastic | Weakness | 4.39% |
| Alert | Time |
|---|---|
| Possible NR7 | about 15 hours ago |
| Possible Inside Day | about 15 hours ago |
| 2x Volume Pace | about 19 hours ago |
| 3x Volume Pace | about 19 hours ago |
| 5x Volume Pace | about 19 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/06/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.89 |
| 52 Week Low | 1.66 |
| Average Volume | 66,491 |
| 200-Day Moving Average | 3.62 |
| 50-Day Moving Average | 4.42 |
| 20-Day Moving Average | 4.56 |
| 10-Day Moving Average | 4.31 |
| Average True Range | 0.41 |
| RSI (14) | 43.50 |
| ADX | 26.26 |
| +DI | 18.55 |
| -DI | 26.35 |
| Chandelier Exit (Long, 3 ATRs) | 4.59 |
| Chandelier Exit (Short, 3 ATRs) | 4.66 |
| Upper Bollinger Bands | 5.76 |
| Lower Bollinger Band | 3.36 |
| Percent B (%b) | 0.28 |
| BandWidth | 52.43 |
| MACD Line | -0.17 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.1352 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.19 | ||||
| Resistance 3 (R3) | 4.19 | 4.14 | 4.17 | ||
| Resistance 2 (R2) | 4.14 | 4.10 | 4.14 | 4.16 | |
| Resistance 1 (R1) | 4.09 | 4.08 | 4.12 | 4.09 | 4.15 |
| Pivot Point | 4.04 | 4.04 | 4.05 | 4.04 | 4.04 |
| Support 1 (S1) | 3.99 | 4.00 | 4.02 | 3.99 | 3.93 |
| Support 2 (S2) | 3.94 | 3.98 | 3.94 | 3.92 | |
| Support 3 (S3) | 3.89 | 3.94 | 3.92 | ||
| Support 4 (S4) | 3.89 |
